Pfizer’s lung cancer drug fails to meet trial objectives

Dacomitinib, Pfizer’s candidate for the treatment of advanced non-small cell lung cancer, has produced disappointing results in late-stage clinical trials, the company has said.

In a comparative trial versus erlotinib, the Pfizer drug failed to show a statistically significant improvement in progression-free survival. Dacomitinib also failed to prolong cancer survival in a placebo-controlled trial.

In other media coverage about Pfizer today, Forbes has analysed its expectations for the pharma giant’s fourth-quarter earnings for 2013, due to be announced tomorrow, 28th January.

“The mid-point of full-year guidance suggests that Pfizer may earn revenues of close to $51.3 billion for the full year 2013, down roughly 13% from 2012.”

Trefis Team, contributor, Forbes.




Related news:

Pfizer lung cancer treatment misses goals in two studies (The Wall Street Journal).

Pfizer says lung cancer drug fails two late-stage studies (Reuters).

Pfizer earnings preview: cost-cutting to offset patent losses (Forbes).

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.